
The FDA is requiring new labeling across all GLP-1 receptor agonists to warn of a potential increased risk of a rare, vision-threatening optic nerve condition.
Catch up on any of the neurology news headlines you may have missed over the course of July 2024, compiled all into one place by the NeurologyLive® team.
The FDA was busy in July 2024, making a number of decisions on potential new therapeutic agents including granting approvals, designations, and clearances.



